Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 08:05 ET | Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Palisade Bio Appoints Margery Fischbein to its Board of Directors
May 07, 2024 08:30 ET | Palisade Bio, Inc.
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...